Medicine for relieving doxorubicin heart injury

The invention discloses an application of an MARCH2 gene expression promoter in preparation of a medicine for relieving adriamycin heart injury. Experiments prove that the MARCH2 gene expression promoter can alleviate cardiac dysfunction related to doxorubicin cardiotoxicity, reduce cardiac fibrosis induced by doxorubicin and inhibit cardiac muscle cell atrophy and apoptosis caused by doxorubicin, which prompts that the MARCH2 gene expression promoter can alleviate doxorubicin heart injury and increase the safety of doxorubicin chemotherapy; the clinical application prospect is realized. 本发明公开了MARCH2基因表达促进剂在制备减轻阿霉素心脏损伤的药物中的应用。实验证明，MARCH2基因表达促进剂能够减轻阿霉素心脏毒性相关的心脏功能障碍，减少阿霉素诱发的心脏纤维化，抑制阿霉素引起的心肌细胞萎缩和凋亡，提示MARCH2基因表达促进剂能够减轻阿霉素心脏损伤，增加了阿霉素化疗的安全性，具有临床应用前景。